Befejeződött2. fázis
Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)
A legfontosabb adatok
- Ki végzi
- VA Office of Research and Development
- Hol
- San Francisco és Tuscaloosa (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 39 fő vett részt
- Kezdés
- 2022. okt. 15.
- Befejezés
- 2026. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- CORT108297
- Placebo
- A regiszteradat frissítve
- 2026. október 27.
Ki vehet részt
- Életkor
- 18 év – 69 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 34 feltétel megnézéseKevesebb
Ki vehet részt
- History of US military service
- Capable of reading and understanding English
- Able to provide written informed consent
- Symptoms of post-traumatic stress disorder (must score 23 or greater on the CAPS-5 assessment at screening visit)
- Men and pre-menopausal women must agree to use two forms of reliable contraception, one of which is a barrier method
- Participants who use an SSRI or SNRI medication for PTSD must be on a stable dose for 8 weeks before enrollment
- Participants who use trazodone for sleep must be on a stable dose
- Participants who use opiate pain medication must be on a stable dose
- For participants who are in psychotherapy, treatment must be stable for 6 weeks
Ki nem vehet részt
- Currently using certain antidepressant medications such as doxepin or tricyclics
- Currently using certain mood stabilizers, such as lithium
- Currently using antipsychotic medication
- Currently using corticosteroid medication (oral or inhaled)
- Use of certain medications that can interfere with the effects of the study drug
- High blood pressure that is not controlled by medication
- Alcohol use that meets criteria for Alcohol Use Disorder in past 3 months
- Marijuana or other drug use that meets criteria for Substance Use Disorder in past 3 months
- Ever diagnosed with: Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Obsessive-Compulsive Disorder, or Major Depressive Disorder with Psychotic Features
- History of neurological disease
- Angina, congestive heart failure or low blood pressure
- Heart attack in the past 6 months
- Heart block or irregular heartbeat
- Kidney failure, liver failure or pancreatitis
- Severe chronic obstructive pulmonary disease (COPD)
- Use of certain medications that can affect heart rhythm
- Diabetes that is not well-controlled
- History of certain types of head injuries
- Mild cognitive impairment
- History of liver disease with lab results on AST or ALT more than 2 times the normal readings
- History of kidney disease with lab results on eGFR less than 60 ml/min
- History of additional risk factors for Torsades de pointes, such as heart failure, low potassium, or family history of a heart rhythm disorder called long QT syndrome
- Experienced any psychologically traumatic event in the past 3 months
- High risk for suicide or violent behavior
- Has sleep apnea and not using any treatment, such as continuous positive airway pressure (CPAP)
Helyszínek itt: Egyesült Államok
- San Francisco VA Medical Center, San Francisco, CASan Francisco, Egyesült Államok
- Tuscaloosa VA Medical Center, Tuscaloosa, ALTuscaloosa, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.
A vizsgálat 2 csoportja
- CORT108297A vizsgált kezelés
CORT108297- 180 milligrams (mg) daily for 7 days
- PlaceboPlacebo, összehasonlításként
Placebo- 180 milligrams (mg) daily for 7 days
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD)
- A regiszteradat frissítve
- 2026. október 27.